Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study
S. Monestier(Hôpital de la Timone), Brigitte Dréno(Nantes Université), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), S. Dalac‐Rat(Centre Hospitalier du Mans), J.-P. Arnault(Centre National de la Recherche Scientifique), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), E. Hainaut(Centre Hospitalier Universitaire de Poitiers), Henri Montaudié(Hôpital l'Archet), Émilie Varey(Inserm), Thomas Jouary(Hôpital Saint-André), F. Skowron, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nabahet Ameur(Bristol-Myers Squibb (France)), B. Guillot(Université de Montpellier), P. Combemale(Centre Léon Bérard), Yannick Le Corre(Université Nantes Angers Le Mans), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Caroline Robert(Institut Gustave Roussy), Anne‐Bénédicte Duval Modeste(Hôpital Charles-Nicolle), Amir Khammari(Inserm), N. Bénéton(Centre Hospitalier du Mans)
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k